Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Agnes, Ang"'
Autor:
Agnes Ang, Kristina Hool, Gaston Demonty, Anne Thomas, Peter Gibbs, Paul Ruff, Tae Won Kim, Michael Boedigheimer, Timothy Price, Marc Peeters
Net Change of Mutational Load
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b4f7cce1ccf64061282a10b81e25ac
https://doi.org/10.1158/1078-0432.22468347
https://doi.org/10.1158/1078-0432.22468347
Autor:
Agnes Ang, Kristina Hool, Gaston Demonty, Anne Thomas, Peter Gibbs, Paul Ruff, Tae Won Kim, Michael Boedigheimer, Timothy Price, Marc Peeters
Plasma-Select Sequence Mutations Gene List
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6752a7b6e77c7058233442f5d87924c9
https://doi.org/10.1158/1078-0432.22468335
https://doi.org/10.1158/1078-0432.22468335
Autor:
Jordan Berlin, Darrin Beaupre, Robert A. Beckman, Abdel-Baset Halim, Agnes Ang, Chi-Yuan Wu, Thore Hettmann, Catherine Copigneaux, Lorrin Yee, Vicki Keedy, Lisa Malburg, Naiyer Rizvi, Moacyr Oliveira, Pasi A. Jänne, Patricia LoRusso
PDF - 278K, Supplementary Methods and Materials, QTc prolongation results. Supplementary Figure 1 - QTc prolongation compared with serum U3-1287 concentration. Supplementary Figure 2 - U3-1287-mediated pancreatic xenograft growth inhibition)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8088012567f918b89bc000dffe8b6149
https://doi.org/10.1158/1078-0432.22451111
https://doi.org/10.1158/1078-0432.22451111
Autor:
Jordan Berlin, Darrin Beaupre, Robert A. Beckman, Abdel-Baset Halim, Agnes Ang, Chi-Yuan Wu, Thore Hettmann, Catherine Copigneaux, Lorrin Yee, Vicki Keedy, Lisa Malburg, Naiyer Rizvi, Moacyr Oliveira, Pasi A. Jänne, Patricia LoRusso
Purpose: HER3 is a key dimerization partner for other HER family members, and its expression is associated with poor prognosis. This first-in-human study of U3-1287 (NCT00730470), a fully human anti-HER3 monoclonal antibody, evaluated its safety, tol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50cdcfb073e4b7eaee807ce3fdcab11e
https://doi.org/10.1158/1078-0432.c.6522104.v1
https://doi.org/10.1158/1078-0432.c.6522104.v1
Autor:
Agnes Ang, Kristina Hool, Gaston Demonty, Anne Thomas, Peter Gibbs, Paul Ruff, Tae Won Kim, Michael Boedigheimer, Timothy Price, Marc Peeters
Purpose:Mutations in EGFR pathway genes are poor prognostic indicators in patients with metastatic colorectal cancer. Plasma analysis of cell-free DNA is a minimally invasive and highly sensitive method to detect somatic mutations in tumors.Experimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1441860af4dd72a213f21a13a1366e5e
https://doi.org/10.1158/1078-0432.c.6526902.v1
https://doi.org/10.1158/1078-0432.c.6526902.v1
Autor:
Christine M. Parseghian, Ryan Sun, Melanie Woods, Stefania Napolitano, Hey Min Lee, Jumanah Alshenaifi, Jason Willis, Shakayla Nunez, Kanwal P. Raghav, Van K. Morris, John P. Shen, Madhulika Eluri, Alexey Sorokin, Preeti Kanikarla, Eduardo Vilar, Marko Rehn, Agnes Ang, Teresa Troiani, Scott Kopetz
PURPOSE Acquired resistance to anti–epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations in KRAS/NRAS/EGFR, among other MAPK-pathway membe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad7568a1d1d032bae5d1f98af201f2d0
https://hdl.handle.net/11591/497629
https://hdl.handle.net/11591/497629
Autor:
Chuanchuan Li, Britta Weigelt, Mark Li, Elisa de Stanchina, Yonina R. Murciano-Goroff, Kanika Arora, Lee P. Lim, Jorge S. Reis-Filho, Jenny Y. Xue, Dongsung Kim, Rohan S. Roy, Yulei Zhao, Michael F. Berger, Amber Bahr, Ann E. Sisk, Brian Loomis, Deanna Mohn, Pragathi Achanta, Trang Thi Mai, Agnes Ang, Bob T. Li, Arnaud Da Cruz Paula, Gregory J. Riely, Kathryn C. Arbour, Jessica Lucas, Piro Lito, J. Russell Lipford, Anne Y. Saiki
Publikováno v:
Nature
Inactive state-selective KRAS(G12C) inhibitors1–8 demonstrate a 30–40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer9. The genetic basis for resistance to these first-in-class muta
Autor:
Christine M, Parseghian, Ryan, Sun, Melanie, Woods, Stefania, Napolitano, Hey Min, Lee, Jumanah, Alshenaifi, Jason, Willis, Shakayla, Nunez, Kanwal P, Raghav, Van K, Morris, John P, Shen, Madhulika, Eluri, Alexey, Sorokin, Preeti, Kanikarla, Eduardo, Vilar, Marko, Rehn, Agnes, Ang, Teresa, Troiani, Scott, Kopetz
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Acquired resistance to anti-epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations inWe analyzed paired plasma samples from patients withPatie
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0198329 (2018)
BACKGROUND:Despite a more proactive approach to reducing new HIV infections in infants through lifelong treatment (Option B+ policy) for infected pregnant women, prevention of mother-to-child transmission of HIV (PMTCT) has not been fully effective i
Externí odkaz:
https://doaj.org/article/6a0fa0484ec44d1ca2600e81fae3211b
Autor:
Grace K. Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S. Falchook, Antoine Italiano, Juergen Wolf, Adrian G. Sacher, Toshiaki Takahashi, Suresh S. Ramalingam, Christophe Dooms, Dong-Wan Kim, Alfredo Addeo, Jayesh Desai, Martin Schuler, Pascale Tomasini, Qui Tran, Simon Jones, Agnes Ang, Abraham Anderson, Antreas A. Hindoyan, David S. Hong, Bob T. Li
Publikováno v:
Cancer Research. 82:CT008-CT008
Introduction: Sotorasib, a first-in-class KRASG12C inhibitor, has been FDA-approved for adults with KRAS p.G12C-mutated locally advanced or metastatic NSCLC who received prior systemic therapies based on the Phase 1/2 global, single-arm CodeBreaK100